SALT LAKE CITY, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (MYGN), (NASDAQ: MYGN), a leader in genetic testing and precision medicine, continues to empower parents with increased access ...
Please provide your email address to receive an email when new articles are posted on . Cell-free fetal antigen analyses had 100% consistency for 465 calls on antigens in which women were ...
Advances in modern medicine allow us to treat fetuses and newborn babies for genetic or inherited diseases. Advances in modern medicine allow us to treat fetuses and newborn babies for genetic or ...
A new test detecting fetal DNA in a mother?s blood could reduce invasive procedures, such as amniocentesis and removal of tissue from the uterus, to predict birth defects. In “A Non-invasive Test for ...
Two professional societies have released comments on the use of cell-free fetal (cff) DNA noninvasive prenatal testing (NIPT) to detect trisomies in low-risk pregnant women. The statements follow ...
Pregnancy care is now being transformed from its traditional, observational monitoring approach into a proactive, ...
Global Market OverviewThe Global Non-Invasive Prenatal Testing (NIPT) Market is projected to expand at a CAGR of 16% by 2029, ...
A single genetic test could potentially replace the current two-step approach to diagnosing rare developmental disorders in children. This shift could enable earlier diagnoses for families and save ...
Myriad Genetics (MYGN) continues to empower parents with increased access to prenatal testing. SneakPeek is now available over the counter in more than 8,800 retail locations nationwide. The product ...
SneakPeek®, the first at-home early fetal sex test for use at six weeks, is now available at over 8,800 retail locations nationwide SALT LAKE CITY, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results